ClinicalTrials.gg
TerminatedNCT01294007Updated Nov 2, 2022Results posted

Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF)

An interventional study of PureGen Osteoprogenitor Cell Allograft and Autograft bone in Lumbar Degenerative Disc Disease, sponsored by Alphatec Spine, Inc.. Terminated at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Alphatec Spine, Inc. · Not applicable, Interventional, and Treatment

How we know · 3 judgments

Why this study was terminated
Product no longer on the market

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Enrollment
124th of 141
1 · median 57
Started
2011
with 7 others
No phase
90 of 232
15 open now
Registered
58th of 232
by date
Lead sponsor
4 of 232
Alphatec Spine, Inc.

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 124th largest by enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2011, is one of 90 with no phase, and was the 58th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the rate and quality of fusion of PureGen Osteoprogenitor Cell Allograft, compared to autograft bone in instrumented posterolateral fusion (PLF) procedures.

Read the detailed description

This is a prospective, multi-center, observational, self-control study assessing screened and consented subjects undergoing instrumented posterolateral fusion for degenerative disc disease (DDD) at 1 to 2 contiguous levels between L1 and S1.

Patients diagnosed with DDD will be screened for enrollment based on inclusion and exclusion criteria outlined in this protocol. Subjects who are successfully screened and sign an informed consent will undergo PLF surgery utilizing PureGen, Alphagraft ProFuse Demineralized Bone Scaffold (DBS), and ZODIAC, Illico, or Xenon Fixation system (pedicle screw and rod fixation system)

Subjects will be followed at 6 weeks, 3, 6, 12 and 24 month post-operative visits. Standard radiographs will be taken at these visits to evaluate fusion rate and quality. Oswestry Disability Index (ODI) and Visual Analog Scale (VAS) self-assessment questionnaires and neurological exams will be administered to measure pain and function scores. A computerized tomography (CT) scan will be taken at the 6-month to further assess rate and quality of fusion. A conditional 12 and 24 month post operative CT may also be taken. Procedure related and PureGen related adverse events will be monitored throughout the study.

03

Conditions studied

  • Lumbar Degenerative Disc Disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic lumbar degenerative disc disease in up to two contiguous levels between L1 and S1
  • Subjects with back and/or leg pain indicated for posterior stabilization with or without decompression at any level and posterolateral fusion (PLF)
  • Unresponsive to conservative treatment for at least 6 months
  • Radiographic evidence of primary diagnosis

Exclusion criteria

Exclusion Criteria:

  • More than 2 levels requiring posterolateral fusion
  • Spondylolisthesis greater than Grade I
  • Prior failed fusion surgery at any lumbar level(s)
  • Systemic or local infection in the disc or cervical spine, past or present
  • Active systemic disease
  • Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly inhibit bone healing
  • Use of other bone graft, Bone Morphogenetic Protein (BMP) or bone graft substitutes in addition to or in place of those products specified
  • greater than 40
  • Use of post operative Spinal Cord Stimulator (SCS)
  • Known or suspected history of alcohol and/or drug abuse
  • Involved in pending litigation or worker's compensation related to the spine
  • Pregnant or planning to become pregnant during the course of the study
  • Insulin-dependent diabetes mellitus
  • less than duration of study
  • Any significant psychological disturbance that could impair consent process or ability to complete self-assessment questionnaires
  • Undergoing chemotherapy or radiation treatment, or chronic use of oral or injected or prolonged use of non-steroidal anti-inflammatory drugs.
  • Known history of or anaphylactic reaction to dimethyl sulfoxide (DMSO)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Study Graft Composite

    AlphaGraft ProFuse Demineralized Bone Scaffold are soaked in PureGen according to Preparation for Use and handling technique. The graft composite is placed on the randomized study side contralateral to the autograft bone graft per surgeon's standard technique for PLF. The wound is closed according to surgeon's standard technique. Post operative care will be according to the site specific standard of care. An avoidance of heavy physical activity and limitations on working, lifting, bending etc. are common precautions post procedure. The decision to use a post operative orthosis is left to the discretion of the Investigator.

    Biological: PureGen Osteoprogenitor Cell Allograft

  • Active comparator
    Control Graft Composite

    Contralateral to the study graft composite, placement of posterolateral fusion graft composite containing iliac crest bone (5 cc/level/side) and local autograft composite (equal volume split with study side). Supplemental posterior pedicle screw fixation utilizing Zodiac, Illico or Xenon Spinal Fixation system. * A defined volume of iliac crest bone graft (indicated in table 2) is harvested and combined with 50% of the previously harvest morselized local bone * The graft composite is placed on the randomized control side using standard technique for PLF

    Procedure: Autograft bone

Interventions

  • BiologicalPureGen Osteoprogenitor Cell Allograft

    PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.

  • ProcedureAutograft bone

    Iliac Crest and Local Autograft Bone

06

What researchers measure

Primary outcomes

  1. Number of Patients With Fusion

    Number of patients with fusion at the 6- and conditional 12- and 24-month visit

    Time frame: 6, 12 and 24 month

07

Results

Posted Oct 5, 2022

Participant flow

Participant flow — Overall Study
MilestonePatient Enrollment
Started1
Completed1
Not completed0

Outcome measures

PrimaryNumber of Patients With Fusion

Number of patients with fusion at the 6- and conditional 12- and 24-month visit

Time frame:
6, 12 and 24 month
Reported as:
Count of participants · Participants
Number of Patients With Fusion
ParticipantsPatient Enrollment
Number of Patients With Fusion1

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patient Enrollment—0/1 (0%)0/1 (0%)

Baseline characteristics

No controls were included.

Age, Categorical
Age, Categorical(Participants)Study Graft CompositeControl Graft CompositeTotal
<=18 years0—0
Between 18 and 65 years0—0
>=65 years1—1
Age, Continuous
Age, Continuous(years)Study Graft CompositeControl Graft CompositeTotal
Mean71—71
Sex: Female, Male
Sex: Female, Male(Participants)Study Graft CompositeControl Graft CompositeTotal
Female0—0
Male1—1
Region of Enrollment
Region of Enrollment(participants)Study Graft CompositeControl Graft CompositeTotal
United States1—1
08

Study locations

1 site
  • Beverly Hills, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2022, 8 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2011
First posted
Feb 11, 2011
Start
Feb 2011
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Oct 5, 2022
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01294007
Lead sponsor
Alphatec Spine, Inc.
Responsible party
Sponsor
First posted
Feb 11, 2011
Start date
Feb 2011
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Oct 5, 2022
Last update
Nov 2, 2022
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion